about
The evolving small-molecule fluorescent-conjugate toolbox for Class A GPCRsAdenosine-A3 receptors in neutrophil microdomains promote the formation of bacteria-tethering cytonemes.Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells.Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.Fluorophore-tagged GPCR ligands.Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.Insights into low molecular mass organic gelators: a focus on drug delivery and tissue engineering applications.Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ)Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery.GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors.Synthesis, Biological Evaluation, and Utility of Fluorescent Ligands Targeting the μ-Opioid Receptor.Surface engineering of living myoblasts via selective periodate oxidation.Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.Alkylation of Staurosporine to Derive a Kinase Probe for Fluorescence Applications.Effect of a toggle switch mutation in TM6 of the human adenosine A₃ receptor on Gi protein-dependent signalling and Gi-independent receptor internalization.Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism.Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold.Cell-type-specific adhesion onto polymer surfaces from mixed cell populations.Biosynthesis of carbapenem antibiotics: new carbapenam substrates for carbapenem synthase (CarC).Conversion of a non-selective adenosine receptor antagonist into A3-selective high affinity fluorescent probes using peptide-based linkers.Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor.Fluorescently Labeled Morphine Derivatives for Bioimaging Studies.Development of novel fluorescent histamine H1-receptor antagonists to study ligand-binding kinetics in living cells.A Non-imaging High Throughput Approach to Chemical Library Screening at the Unmodified Adenosine-A3 Receptor in Living Cells.New fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells.Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation.Direct visualisation of internalization of the adenosine A3 receptor and localization with arrestin3 using a fluorescent agonist.Highly potent and selective fluorescent antagonists of the human adenosine A₃ receptor based on the 1,2,4-triazolo[4,3-a]quinoxalin-1-one scaffold.Correction to Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.A Thieno[2,3-d]pyrimidine Scaffold is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor.Nucleoside Based Self-Assembling Drugs for Localized Drug Delivery.Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.Developing a self-healing supramolecular nucleoside hydrogel.Gelation properties of self-assembling N-acyl modified cytidine derivativesImmunosuppressive but non-LasR-inducing analogues of the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-l-homoserine lactonePreparation and structural analysis of (±)-cis-ethyl 2-sulfanylidenedecahydro-1,6-naphthyridine-6-carboxylate and (±)-trans-ethyl 2-oxooctahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxylateStructure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor
P50
Q26991781-28F1EF3A-192E-4DCF-A337-FC84F1A9E744Q30542407-EB27E783-343B-4929-96D6-B6A1CC01F1CBQ34706604-0331983E-EB11-4204-B838-3F2B133063C1Q36077035-560407A3-E376-49E1-9CEF-5BD97D3746C7Q36242011-9A9AEDD5-3F88-43F6-9F0C-9EBAF2EDBAEAQ38136285-653D79F6-B1E7-4292-BCC0-6A1591F69F2AQ38197907-0C32E3AF-605D-4330-88DF-65A2CA4BD178Q38641723-F197393C-AB43-4249-B101-53A07BB22CA2Q38765035-1870EB2C-84AE-4487-84B7-E6F95970EBEDQ38827365-4CC204D1-5E0D-4809-A65D-36114A26058DQ38830600-C29E359C-F20A-42DA-A1DB-0EB2B4B49B62Q38935796-52B4E35B-78B2-47DB-8A1B-6EBB868C4979Q40674011-4F2DE7DF-7DEC-4580-9FA3-D0E02AC20AE0Q41571207-C97B9479-26D3-4818-9630-AF601E454F74Q41885302-8569AE2C-1B34-47A9-B59E-E97397707957Q41965453-D2CA3C3C-F20B-45CB-9FD6-33D593D75690Q42176971-210D52E1-5118-4744-A088-AD708A1B7FB1Q42201896-87E7F6B0-B1E3-42EE-9F0F-CDC888D5DE44Q42950461-D3EC543D-3760-4A50-98AD-0CA80DF19C3BQ43186587-352752B8-60CE-4972-ACEB-5C603C45B4EEQ44270513-61DD4CA1-D2C8-43C7-9EE8-0DF6FA191540Q44918723-D4815A1B-2B20-4FF7-ACE4-B0C3E9AC77FDQ46440416-E7CB5D72-500B-4610-944B-4FBFA3AB72F3Q46579329-AE026C6C-F0B6-4F31-BEE8-28F82294090CQ47240793-9640073C-0660-4F37-804F-55106AA6FE3FQ47711109-D1B178B6-FC0C-4CE7-84AF-AA864395B9E4Q49714374-98DEB767-EB58-4655-A0E2-0F1298559E0CQ50707930-3C3EE8C9-C00E-4E5C-B9A0-BE8BE9901432Q51736372-3FDACADC-3C13-4B28-8E0F-939B3BF84266Q51743252-F4DC7067-81BF-4273-B187-F2BF35F98C35Q51761533-C9817AB4-1954-4178-A285-AB3712F4C1E2Q52567133-FFF719AC-91DA-4990-BEB4-7B912B8B6012Q52570516-48E373B7-ABDD-4CAB-831B-4ADA611C2456Q52640271-7434A6BF-8501-4B5F-93A9-7AAB0CA426EFQ52646855-74AB63CC-06E0-43E0-8CF7-B5E9A873275DQ54075328-D2ED781E-3272-449B-B705-E82D24EF3F15Q60433231-BF1C9B60-EBA5-4BED-89D6-8E5C4222A10AQ83848686-F1826EA8-5A09-437F-85DC-DCD9D62F0D5DQ86179877-151FE80B-90B6-42C6-9ECF-28C235B3E499Q90455280-C9ECE0EC-EC25-4ACB-AC9A-6AB8649D2572
P50
description
researcher ORCID ID = 0000-0003-0030-9908
@en
name
Barrie Kellam
@ast
Barrie Kellam
@en
Barrie Kellam
@es
Barrie Kellam
@nl
type
label
Barrie Kellam
@ast
Barrie Kellam
@en
Barrie Kellam
@es
Barrie Kellam
@nl
prefLabel
Barrie Kellam
@ast
Barrie Kellam
@en
Barrie Kellam
@es
Barrie Kellam
@nl
P1153
6603706091
P31
P496
0000-0003-0030-9908